Bührke A, Bär C, Thum T
Institut für Molekulare und Translationale Therapiestrategien (IMTTS), Medizinische Hochschule Hannover, Hannover, Deutschland.
REBIRTH Excellence Cluster, Medizinische Hochschule Hannover, Hannover, Deutschland.
Herz. 2018 Mar;43(2):115-122. doi: 10.1007/s00059-017-4660-4.
As a result of the Human Genome Project it became evident that only 1-3% of all gene transcripts encode proteins. The vast majority of gene transcripts are in fact characterized as non-coding RNAs (ncRNAs). These ncRNAs have a huge impact on diverse physiological and pathological mechanisms within an organism. In particular, microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), which are differentiated by their size and function, are involved in the regulation and development of many illnesses. In the context of heart and cardiovascular diseases numerous ncRNAs have also already been described in some detail. As these molecules represent therapeutic target structures, ncRNAs provide a completely new level for the discovery of promising therapeutic approaches. Many approaches have already been developed aimed at influencing the expression levels of specific ncRNAs in order to induce beneficial effects on pathological processes. In fact, first medications based on miRNAs have already achieved approval. Additionally, ncRNAs contained in plasma can serve as new non-invasive diagnostic markers for the detection of diseases.
人类基因组计划的结果表明,所有基因转录本中只有1-3%编码蛋白质。事实上,绝大多数基因转录本被归类为非编码RNA(ncRNA)。这些ncRNA对生物体中的各种生理和病理机制有巨大影响。特别是,微小RNA(miRNA)和长链非编码RNA(lncRNA),它们根据大小和功能进行区分,参与了许多疾病的调节和发展。在心脏和心血管疾病方面,许多ncRNA也已经得到了较为详细的描述。由于这些分子代表着治疗靶点结构,ncRNA为发现有前景的治疗方法提供了一个全新的层面。已经开发了许多旨在影响特定ncRNA表达水平的方法,以便对病理过程产生有益影响。事实上,首批基于miRNA的药物已经获得批准。此外,血浆中含有的ncRNA可以作为检测疾病的新的非侵入性诊断标志物。